E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part 1: adults and adolescents (12 years and above) - To evaluate safety of twice daily applications of delgocitinib cream in the treatment of adults and adolescents with moderate to severe AD.
Part 2: children (2-11 years) - To evaluate safety of twice daily applications of delgocitinib cream in the treatment of children with moderate to severe AD under maximal usage conditions. |
|
E.2.2 | Secondary objectives of the trial |
Part 1: adults and adolescents (12 years and above) - To evaluate the PK of twice daily applications of delgocitinib cream in adults and adolescents with moderate to severe AD.
Part 2: children (2-11 years) - To evaluate the PK of twice daily applications of delgocitinib cream in children with moderate to severe AD under maximal usage conditions. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above) - Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD - Age 12 years and above at baseline - AD involvement of 25-50% treatable body surface area (BSA) at screening and at baseline - Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline
Key Inclusion criteria (Part 2: children; 2-11 years) - Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD - Age 2-11 years at baseline - History of AD for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years) - AD involvement of ≥35% treatable BSA at screening and at baseline - Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline |
|
E.4 | Principal exclusion criteria |
Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above) - Active dermatologic conditions that may interfere with the diagnosis of AD - Use of tanning beds or phototherapy within 4 weeks prior to baseline - Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline - Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline - Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline - Any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- AEs (number of AEs and number of subjects with AEs) from baseline to Week 8. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Cmax, AUC and tmax at Day 8. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 11 |